FI94341C - Menetelmä terapeuttisesti käyttökelpoisten 5-fenyyli-2-pyrimidinonijohdannaisten valmistamiseksi - Google Patents

Menetelmä terapeuttisesti käyttökelpoisten 5-fenyyli-2-pyrimidinonijohdannaisten valmistamiseksi

Info

Publication number
FI94341C
FI94341C FI875660A FI875660A FI94341C FI 94341 C FI94341 C FI 94341C FI 875660 A FI875660 A FI 875660A FI 875660 A FI875660 A FI 875660A FI 94341 C FI94341 C FI 94341C
Authority
FI
Finland
Prior art keywords
phenyl
preparation
therapeutically useful
pyrimidinone derivatives
ring
Prior art date
Application number
FI875660A
Other languages
English (en)
Swedish (sv)
Other versions
FI94341B (fi
FI875660A0 (fi
FI875660L (fi
Inventor
Nicholas Alex Saccomano
Fredric James Vinick
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of FI875660A0 publication Critical patent/FI875660A0/fi
Publication of FI875660L publication Critical patent/FI875660L/fi
Publication of FI94341B publication Critical patent/FI94341B/fi
Application granted granted Critical
Publication of FI94341C publication Critical patent/FI94341C/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C07D233/38—One oxygen atom with acyl radicals or hetero atoms directly attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/42—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
    • C07D233/78—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/06—1,2,3-Thiadiazoles; Hydrogenated 1,2,3-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Curing Cements, Concrete, And Artificial Stone (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Steroid Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Polymerisation Methods In General (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FI875660A 1986-04-29 1987-12-22 Menetelmä terapeuttisesti käyttökelpoisten 5-fenyyli-2-pyrimidinonijohdannaisten valmistamiseksi FI94341C (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8600958 1986-04-29
PCT/US1986/000958 WO1987006576A1 (en) 1986-04-29 1986-04-29 Calcium independent camp phosphodiesterase inhibitor antidepressant

Publications (4)

Publication Number Publication Date
FI875660A0 FI875660A0 (fi) 1987-12-22
FI875660L FI875660L (fi) 1987-12-22
FI94341B FI94341B (fi) 1995-05-15
FI94341C true FI94341C (fi) 1995-08-25

Family

ID=22195483

Family Applications (2)

Application Number Title Priority Date Filing Date
FI875724A FI875724A0 (fi) 1986-04-29 1986-04-29 Av kalcium oberoende camp fosfodiesteras-inhibitordepressant.
FI875660A FI94341C (fi) 1986-04-29 1987-12-22 Menetelmä terapeuttisesti käyttökelpoisten 5-fenyyli-2-pyrimidinonijohdannaisten valmistamiseksi

Family Applications Before (1)

Application Number Title Priority Date Filing Date
FI875724A FI875724A0 (fi) 1986-04-29 1986-04-29 Av kalcium oberoende camp fosfodiesteras-inhibitordepressant.

Country Status (28)

Country Link
EP (1) EP0247725B1 (fi)
JP (1) JPH0645602B2 (fi)
KR (1) KR900002064B1 (fi)
CN (1) CN1018827B (fi)
AT (1) ATE102189T1 (fi)
AU (1) AU576448B2 (fi)
CA (1) CA1331606C (fi)
CZ (1) CZ280146B6 (fi)
DD (3) DD280321A5 (fi)
DE (1) DE3789164T2 (fi)
DK (1) DK172033B1 (fi)
EG (1) EG18239A (fi)
ES (1) ES2061492T3 (fi)
FI (2) FI875724A0 (fi)
HU (1) HU215433B (fi)
IE (1) IE63170B1 (fi)
IL (1) IL82342A (fi)
IN (1) IN167587B (fi)
MY (2) MY102842A (fi)
NO (2) NO875441D0 (fi)
NZ (1) NZ220106A (fi)
PH (1) PH25107A (fi)
PL (1) PL153225B1 (fi)
PT (1) PT84766B (fi)
SU (2) SU1646488A3 (fi)
WO (1) WO1987006576A1 (fi)
YU (4) YU47969B (fi)
ZA (1) ZA873014B (fi)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8610531D0 (en) * 1986-04-30 1986-06-04 Fbc Ltd Herbicides
DE3823299A1 (de) * 1988-07-07 1990-01-11 Schering Ag Substituierte phenyl-pyrrolidin-2-one, -oxazolidin-2-one und -imidazolidin-2-one, ihre herstellung sowie verwendung in arzneimitteln
WO1991007177A1 (en) * 1989-11-13 1991-05-30 Pfizer Inc. Pyrimidone derivatives and analogs in the treatment of asthma or certain skin disorders
RU2104306C1 (ru) * 1989-11-13 1998-02-10 Пфайзер Инк. Способ получения оптически активного (2s)- или (2r)-эндо-бицикло[2.2.1]гептан-2-ола, способ получения 5-(3-[(2r)-экзо-бицикло[2.2.1]гепт-2-илокси]-4-метоксифенил)-3,4,5,6-тетрагидропиримидин-2(1н)-она, оптически активный 5-(3-[экзо-бицикло[2.2.1]гепт-2-илокси]4-метоксифенил)-3,4,5,6-тетрагидропиримидин-2(1н)-он, оптически активные промежуточные соединения и способ их получения
EP0542795B1 (en) * 1990-08-03 1998-01-07 Smithkline Beecham Corporation Tnf inhibitors
US5124455A (en) * 1990-08-08 1992-06-23 American Home Products Corporation Oxime-carbamates and oxime-carbonates as bronchodilators and anti-inflammatory agents
CA2095429A1 (en) * 1990-11-06 1992-05-07 Paul E. Bender Imidazolidinone compounds
US5547979A (en) * 1992-03-30 1996-08-20 Smithkline Beecham TNF inhibition
US5395935A (en) * 1992-05-08 1995-03-07 Pfizer Inc. Endo-bicyclo[2.2.1]heptan-2-ol and derived pharmaceutical agents
GB9212673D0 (en) * 1992-06-15 1992-07-29 Celltech Ltd Chemical compounds
GB9222253D0 (en) * 1992-10-23 1992-12-09 Celltech Ltd Chemical compounds
US5814651A (en) * 1992-12-02 1998-09-29 Pfizer Inc. Catechol diethers as selective PDEIV inhibitors
DK0672031T3 (da) * 1992-12-02 2003-06-10 Pfizer Catecholdiethere som selektive PDE IV-inhibitorer
GB9226830D0 (en) * 1992-12-23 1993-02-17 Celltech Ltd Chemical compounds
US5622977A (en) * 1992-12-23 1997-04-22 Celltech Therapeutics Limited Tri-substituted (aryl or heteroaryl) derivatives and pharmaceutical compositions containing the same
GB9304919D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
GB9304920D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
US5665754A (en) * 1993-09-20 1997-09-09 Glaxo Wellcome Inc. Substituted pyrrolidines
JP3398152B2 (ja) * 1993-10-12 2003-04-21 ブリストル‐マイヤーズ・スクイブ・ファーマ・カンパニー １ｎ−アルキル−ｎ−アリールピリミジンアミンおよびその誘導体
JP2818820B2 (ja) * 1993-11-26 1998-10-30 ファイザー・インク． 抗炎症剤としての３−アリール−２−イソオキサゾリン類
US5502072A (en) * 1993-11-26 1996-03-26 Pfizer Inc. Substituted oxindoles
GB9326173D0 (en) * 1993-12-22 1994-02-23 Celltech Ltd Chemical compounds and process
WO1995017399A1 (en) * 1993-12-22 1995-06-29 Celltech Therapeutics Limited Trisubstituted phenyl derivatives, processes for their preparation and their use as phosphodiesterase (type iv) inhibitors
AU1326795A (en) * 1994-03-09 1995-09-25 Pfizer Inc. Isoxazoline compounds as 5-lipoxygenase inhibitors
JPH09505082A (ja) * 1994-03-09 1997-05-20 ファイザー・インコーポレーテッド Ｔｎｆ放出の阻害剤としてのイソオキサゾリン
US5786354A (en) * 1994-06-21 1998-07-28 Celltech Therapeutics, Limited Tri-substituted phenyl derivatives and processes for their preparation
US6245774B1 (en) 1994-06-21 2001-06-12 Celltech Therapeutics Limited Tri-substituted phenyl or pyridine derivatives
GB9412573D0 (en) 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9412571D0 (en) * 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9412672D0 (en) * 1994-06-23 1994-08-10 Celltech Ltd Chemical compounds
US5922751A (en) 1994-06-24 1999-07-13 Euro-Celtique, S.A. Aryl pyrazole compound for inhibiting phosphodiesterase IV and methods of using same
AU704116B2 (en) * 1994-08-05 1999-04-15 Pfizer Inc. Processes and intermediates in the synthesis of 5-(3-{exo-bicyclo{ 2.2.1}hept-2-yloxy}-4-methoxyphenyl)- 3,4,5 ,6-tetrahydropyrimidin-2(1h)-one
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
GB9526246D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526245D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
DE19617864A1 (de) * 1996-04-23 1997-10-30 Schering Ag Neue chirale Phenyldihydrofuranone
GB9608435D0 (en) * 1996-04-24 1996-06-26 Celltech Therapeutics Ltd Chemical compounds
US6294541B1 (en) 1996-06-06 2001-09-25 Euro-Celtique S.A. Purine derivatives having phosphodiesterase IV inhibition activity
DE69730980T2 (de) 1996-07-31 2006-02-23 Nikken Chemicals Co., Ltd. 6-phenyltetrahydro-1,3-oxazin-2-on derivate und medizinische zusammensetzungen, die sie enthalten
US6265402B1 (en) 1996-08-27 2001-07-24 Nikken Chemicals Co., Ltd. Use of 2-phenylmorpholin-5-one derivatives
US5744473A (en) * 1996-09-16 1998-04-28 Euro-Celtique, S.A. PDE IV inhibitors: "bis-compounds"
GB9619284D0 (en) * 1996-09-16 1996-10-30 Celltech Therapeutics Ltd Chemical compounds
GB9622363D0 (en) 1996-10-28 1997-01-08 Celltech Therapeutics Ltd Chemical compounds
GB9625184D0 (en) * 1996-12-04 1997-01-22 Celltech Therapeutics Ltd Chemical compounds
JP2001507349A (ja) 1996-12-23 2001-06-05 セルテック セラピューティックス リミテッド 縮合多環式２−アミノピリミジン誘導体、それらの製造およびたんぱく質チロシンキナーゼ抑制因子としてのそれらの使用
GB9705361D0 (en) * 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
GB9713087D0 (en) * 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
CA2313004A1 (en) 1997-12-12 1999-06-24 David Cavalla 3-substituted adenines via2-thioxanthines
US6319928B1 (en) 1998-11-30 2001-11-20 Euro-Celtique, S.A. Purine derivatives having phosphodiesterase IV inhibition activity
AU4053800A (en) 1999-04-02 2000-10-23 Euro-Celtique S.A. Purine derivatives having phosphodiesterase iv inhibition activity
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
GB9924862D0 (en) 1999-10-20 1999-12-22 Celltech Therapeutics Ltd Chemical compounds
KR100874791B1 (ko) 2001-05-29 2008-12-18 바이엘 쉐링 파마 악티엔게젤샤프트 Ｃｄｋ-억제 피리미딘, 그의 제조방법 및 약제로서의 용도
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
RU2237662C1 (ru) * 2003-06-05 2004-10-10 Федеральное государственное унитарное предприятие "Государственный научный центр "Научно-исследовательский институт органических полупродуктов и красителей" Способ получения 1-ацетил-2-имидазолидона
KR100753017B1 (ko) * 2006-05-25 2007-08-30 한국화학연구원 7-(3,4-디알콕시페닐)-피라졸로[1,5-ａ]피리미딘 화합물을포함하는 관절염, 아토피 피부염, 백혈병을 포함한 암 및알쯔하이머, 우울증 또는 기억력 감소 등의 뇌질환의 치료및 예방을 위한 약제학적 조성물
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
AU2008261102B2 (en) 2007-06-04 2013-11-28 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP3239170B1 (en) 2008-06-04 2019-03-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
JP2011144169A (ja) * 2009-12-18 2011-07-28 Ishihara Sangyo Kaisha Ltd イミダゾピリミジン誘導体又はその塩、並びにそれらを含有する有害生物防除剤
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CA3100941C (en) 2011-03-01 2024-03-05 Synergy Pharmaceuticals Inc. Process of preparing guanylate cyclase c agonists
CN102731411B (zh) * 2012-06-15 2014-10-22 湖南大学 4-烷基-6-芳基-3,4-二氢嘧啶-2-硫酮的制备及其作为抗抑郁药物的应用
WO2014131024A2 (en) 2013-02-25 2014-08-28 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
HRP20240805T1 (hr) 2013-06-05 2024-09-27 Bausch Health Ireland Limited Ultra-pročišćeni agonisti guanilat-ciklaze c, postupak njihove pripreme i uporabe
CN114404588A (zh) 2013-08-09 2022-04-29 阿德利克斯公司 用于抑制磷酸盐转运的化合物和方法
CN114340631A (zh) 2019-05-21 2022-04-12 阿德利克斯股份有限公司 用于降低患者的血清磷酸盐的组合

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1451154A (fr) * 1959-06-22 1966-01-07 Guy Hue Lab Nouveaux dérivés pyrazoliques et leur procédé de préparation
NL136620C (fi) * 1963-04-30
US3923833A (en) * 1968-05-01 1975-12-02 Hoffmann La Roche N-{8 (1-cyano-2-phenyl)ethyl{9 carbamates
BE759176A (fr) * 1969-11-20 1971-05-19 Sandoz Sa Derives de la pyrimidine, leur preparation et medicaments contenant cesderives
US3636039A (en) * 1970-02-24 1972-01-18 Hoffmann La Roche Substituted benzylimidazolidinones
DE2413935A1 (de) * 1974-03-20 1975-10-16 Schering Ag 4-(polyalkoxy-phenyl)-2-pyrrolidone
US4193926A (en) * 1974-03-20 1980-03-18 Schering Aktiengesellschaft 4-(Polyalkoxy phenyl)-2-pyrrolidones
IE40911B1 (en) * 1974-04-11 1979-09-12 Schering Ag Imidazole derivatives and process for their manufacture
DE2541855A1 (de) * 1975-09-18 1977-03-31 Schering Ag 4-(polyalkoxy-phenyl)-2-pyrrolidone ii
SU888821A3 (ru) * 1976-12-03 1981-12-07 Шеринг Аг (Инофирма) Способ получени 5-(замещенный фенил)-оксазолидинонов или их серусодержащих аналогов
HU179019B (en) * 1978-11-01 1982-08-28 Gyogyszekutato Intezet Process for preparing 4-//3,4-dialkoxy-phenyl/-alkyl/- 2imidazolidinone derivatives
US4261995A (en) * 1979-08-31 1981-04-14 Syntex (U.S.A.) Inc. 4-Phenyl-and 5-phenyl-1,4,5,6-tetrahydropyrimidine derivatives
DE3130633A1 (de) * 1981-08-01 1983-02-17 Basf Ag, 6700 Ludwigshafen 7-amino-azolo(1,5-a)pyrimidine und diese enthaltende fungizide
DE3315797A1 (de) * 1983-04-30 1984-10-31 Beiersdorf Ag, 2000 Hamburg Substituierte phenyl-2-(1h)-pyrimidinone, verfahren zu ihrer herstellung und ihre verwendung sowie diese verbindungen enthaltende zubereitungen
JPS6019789A (ja) * 1983-07-12 1985-01-31 Kyorin Pharmaceut Co Ltd イミダゾ〔１，５−ａ〕ピリミジン誘導体

Also Published As

Publication number Publication date
YU47195B (sh) 1995-01-31
FI94341B (fi) 1995-05-15
NO173138C (no) 1993-11-03
FI875724A7 (fi) 1987-12-28
NZ220106A (en) 1991-08-27
FI875724L (fi) 1987-12-28
DK215087D0 (da) 1987-04-28
JPH0645602B2 (ja) 1994-06-15
EP0247725B1 (en) 1994-03-02
JPS62281864A (ja) 1987-12-07
KR870010009A (ko) 1987-11-30
IL82342A (en) 1992-03-29
PL153225B1 (en) 1991-03-29
ZA873014B (en) 1988-12-28
FI875660A0 (fi) 1987-12-22
FI875660L (fi) 1987-12-22
YU47969B (sh) 1996-08-13
DE3789164D1 (de) 1994-04-07
ES2061492T3 (es) 1994-12-16
NO875441D0 (no) 1987-12-28
YU115788A (en) 1988-10-31
DD280319A5 (de) 1990-07-04
CN1018827B (zh) 1992-10-28
NO173138B (no) 1993-07-26
YU115688A (en) 1988-10-31
PH25107A (en) 1991-02-19
SU1653542A3 (ru) 1991-05-30
DK215087A (da) 1987-10-30
FI875724A0 (fi) 1987-12-28
YU77387A (en) 1988-10-31
IN167587B (fi) 1990-11-17
IE871036L (en) 1987-10-29
WO1987006576A1 (en) 1987-11-05
PT84766A (en) 1987-05-01
CZ280146B6 (cs) 1995-11-15
DE3789164T2 (de) 1994-06-09
YU46916B (sh) 1994-06-24
NO875440D0 (no) 1987-12-28
YU46915B (sh) 1994-06-24
SU1646488A3 (ru) 1991-04-30
EP0247725A3 (en) 1990-01-17
PT84766B (pt) 1989-12-29
PL265397A1 (en) 1988-07-21
CA1331606C (en) 1994-08-23
MY106638A (en) 1995-07-31
HU215433B (hu) 2000-05-28
DD280321A5 (de) 1990-07-04
ATE102189T1 (de) 1994-03-15
CZ298987A3 (en) 1995-05-17
CN87103225A (zh) 1987-11-11
DK172033B1 (da) 1997-09-22
EP0247725A2 (en) 1987-12-02
HUT63150A (en) 1993-07-28
AU576448B2 (en) 1988-08-25
MY102842A (en) 1993-03-31
DD273773A5 (de) 1989-11-29
KR900002064B1 (ko) 1990-03-31
NO875440L (no) 1987-12-28
EG18239A (en) 1992-10-30
IE63170B1 (en) 1995-03-22
AU7214287A (en) 1987-12-10
YU115588A (en) 1988-10-31

Similar Documents

Publication Publication Date Title
FI94341C (fi) Menetelmä terapeuttisesti käyttökelpoisten 5-fenyyli-2-pyrimidinonijohdannaisten valmistamiseksi
ATE172201T1 (de) Morphinan-derivate und medizinische verwendung
ES8401032A1 (es) Procedimiento para la obtencion de 1,4-dihidropiridinas.
FI892497A0 (fi) Menetelmä terapeuttisesti aktiivisten bentsamidijohdannaisten valmistamiseksi
ATE86623T1 (de) 8-azabicyclo(3,2,1>octan- und 9azabicyclo(3,3,1>nonanderivate.
DK491089A (da) Benzoxazepinon og fremgangsmaade til fremstilling deraf samt mellemprodukt til brug i fremgangsmaaden
SE7606424L (sv) Substituerade bensamider
FR2639944B1 (fr) Nouveaux derives de l'indole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP0449011A3 (en) Stereoselective process for the preparation of 2-amino-ethanol derivatives having a central analgesic activity and intermediates thereof
SU1624959A1 (ru) 5-(β-П-МЕТОКСИФЕНИЛ-β-ОКСИЭТИЛ)-2-МЕТИЛТИО-1-МЕТИЛ-4,5,6,7-ТЕТРАГИДРОИ МИДАЗО[4,5-C]ПИРИДИНА ДИГИДРОХЛОРИД, ОБЛАДАЮЩИЙ ГИПОТЕНЗИВНЫМ, АНТИГИПЕРТЕНЗИВНЫМ, СПАЗМОЛИТИЧЕСКИМ И СЕДАТИВНЫМ ДЕЙСТВИЕМ
FI850401L (fi) Maettade tricykliska kvaevehaltiga dioner saosom medel foer aktivering av fattningsfoeremaogan.

Legal Events

Date Code Title Description
BB Publication of examined application
FG Patent granted

Owner name: PFIZER INC.

MA Patent expired